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Nonclinical Development Needs and Regulatory 
Requirements for Multipurpose Prevention Technologies: 
A Primer 
By Joe Romano, Martha Brady, and Judy Manning
As enthusiasm grows for the development of products 
that address sexual and reproductive health (SRH) needs 
around the world, innovative development strategies are 
needed that are efficient, cost-effective, and consistent 
with likely regulatory requirements for such products. 
Such strategies will be even more critical as combination 
products are developed that seek to address multiple 
health indications simultaneously, and combine drugs and/
or devices that may be approved and/or experimental—
the prospect of which is truly a multidimensional 
regulatory puzzle.
This summary outlines key development elements 
necessary for various configurations of multipurpose 
prevention technology (MPT) products for the 
simultaneous prevention of Human Immunodeficiency 
Virus (HIV), other sexually transmitted infections (STIs), 
and/or pregnancy.  The studies and activities described 
in this summary regarding drug substances (DS) and 
drug products (DP) are necessary to satisfy the content 
requirements for Section 7 of an Investigational New Drug 
(IND) application (Chemistry, 
Manufacture, Control [CMC]). 
For an initial IND submission, 
the CMC content must support 
the safety of the product (purity, 
stability, toxic impurities). Later 
on, DS and DP manufacture will 
need to satisfy International 
Conference on Harmonization 
(ICH) guidances Q8,1 Q9,2 and 
Q10,3 which will be part of the 
Quality System necessary for 
commercialization.  
Key elements of MPT product 
development will be the assurance 
of the quality and safety of DS 
and DP, which can be achieved by 
proper preclinical (also referred to 
as nonclinical) evaluations of safety 
and toxicity, as well as by achieving necessary quality standards 
regarding the CMC for drug substances and drug products. 
We consider key development issues up through but 
not including Phase I clinical studies. Clinical evaluation 
strategies for MPT products will be determined by several 
factors, including specific product configuration and 
properties; however, these issues are beyond the scope of 
this paper. Here, we focus on the nonclinical development 
needs and potential regulatory requirements for MPTs.
Combination pharmaceutical products have development 
and regulatory complexity beyond that of single-agent, single-
indication products.  The presence of more than one active 
pharmaceutical ingredient (API) increases the nonclinical, 
quality (CMC), and clinical development obligations for 
such a product.  This is further compounded when a 
combination product targets more than one medical 
indication, such as MPTs designed as either drug+drug or 
drug+device combinations to protect against HIV, other 
STIs, and unintended pregnancy (see Figure 1). 
Figure 1  MPT pathway: A typology
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Product Configuration Options 
Contraceptive products exist in a number of 
configurations and delivery strategies, including systemic 
formulations (oral pills, injectables, implants), topical 
dosage forms (gels, films, vaginal rings), intrauterine devices 
(with and without hormones), and physical barriers (male 
and female condoms, diaphragms, cervical caps).  These 
products rely on either hormonal or nonhormonal API, 
and achieve effect via systemic or topical delivery. Current 
HIV pre-exposure prophylaxis (PrEP) products follow 
similar product design options for dosing and delivery, 
including systemic (oral, injectable), topical (gel, tablets, 
vaginal rings), and physical barrier (diaphragm, female 
condom).  Although oral and topical strategies for STI 
prevention exist, the development of these strategies has 
not been as robust as HIV PrEP product development.
Status of selected products 
A number of licensed contraceptive products exist, 
including an array of hormonal products.  Although no 
HIV-prevention products (other than condoms) have yet 
to achieve regulatory licensure, a number of antiretrovirals 
(ARVs) approved for treatment of acute (post-exposure 
prophylaxis [PEP]) or chronic HIV infection are in clinical 
evaluation as prevention products (e.g., tenofovir,4 
maraviroc5,6). However, there are a number of HIV-
prevention candidate products in development involving 
API that have not been approved for treatment (e.g., 
MIV-150,7 dapivirine8). Similarly, some early-stage product 
development efforts for new contraceptive agents (e.g., 
nonhormonal chemical entities9) are also pre-licensure. 
MPT products can be developed from various combinations 
of approved and/or experimental drugs and/or devices for 
different single indications.  The development requirements 
for products that do or do not involve already approved 
components will differ accordingly. In the case of MPTs, 
the variable development burdens for products with API 
that are in different stages of single-indication approval are 
potentially complicated further if the product is configured 
in a novel delivery device. For example, co-formulation 
of an approved combination oral contraceptive pill with 
a drug approved for treatment of HIV infection will 
have different development requirements and timelines 
than a vaginal ring designed to release an experimental 
nonhormonal contraceptive and an experimental ARV (see 
Figure 2). 
Abbreviations
API Active pharmaceutical ingredient
ARV Antiretroviral
AUC Area under curve
CDER  Center for Drug Evaluation and Research
CDRH  Center for Devices and Radiological Health
Cmax Maximum concentration
CMC  Chemistry, manufacture, control
DOE Design of experiment
DP Drug product
DS Drug substance 
EC50 Effective concentration, 50%
EMA  European Medicines Agency
FDA US Food and Drug Administration
GMP Good manufacturing practice
HIV Human immunodeficiency virus
ICH International Conference on Harmonization
IND Investigational new drug (application)
MoA Mechanism of action
MPT Multipurpose prevention technology
NDA New drug application
NDE New drug entity





QBD Quality by design
STI Sexually transmitted infection
T1/2 Half-life; time to 50% reduction
Tmax Time to maximum concentration
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While specific development requirements will vary with each 
MPT product, the broad perspectives of 1) experimental 
versus approved, 2) drug versus device, and 3) 
systemic versus topical delivery provide the basis for the 
development of general guidelines that could help to inform 
the broad spectrum of possible MPT product development 
strategies. 
The following sections provide a description of 
development needs for possible MPT product components 
in terms of nonclinical safety and quality issues. 
MPT Case Study Number 1:  
Co-formulation of approved drugs/
products
Nonclinical activity
Perhaps the simplest, quickest, and least expensive 
MPT product development effort would involve the 
co-formulation of drugs and/or devices already approved 
for the different individual indications being targeted by 
the combination. (Although male and female condoms 
are effective HIV-prevention products, neither is currently 
considered a potential component of first-generation MPT 
products.) Further, because no drugs are yet approved 
for prevention of HIV, first-generation MPT products will 
likely involve drugs approved for 
treatment of HIV (or STI). 
Regulators’ primary concerns are 
the potential for: 1) toxicological 
and 2) pharmacokinetic (PK) 
interactions. If there is experience 
of co-administration, there is no 
longer concern; if not, each of 
these should be addressed.  The 
ICH guideline provides an 
approach for testing the toxicology 
interaction potential, and PK 
assessment can be included in 
these studies to identify PK 
interactions.  Additionally, any 
product developer will want to 
assess potential pharmacodynamic 
(PD) interactions that may affect 
dosing.
The simplest configuration of such 
an MPT product would be in a 
dosage/delivery form similar to that already available for 
the individual product’s specific indications (e.g., oral HIV 
PEP combined with an oral contraceptive). In this case, 
little, if any, nonclinical safety data beyond what exists for 
each individual product would likely be needed.  The ICH 
M3 guideline10 suggests that where there is adequate clinical 
experience with co-administration of two approved late-stage 
products, combination toxicity studies would generally not be 
recommended to support clinical studies or marketing unless 
there is significant toxicological concern (e.g., target organ 
toxicity). Presumably, the individual products would have 
satisfied regulatory requirements for genotoxicity, acute 
and chronic toxicity, reprotoxicity, and so forth. 
The proposed combination could possibly require 
a nonclinical safety assessment involving fixed plus 
variable doses of the two drugs in an animal system to 
determine if any toxicity is potentially associated with 
the combination.  Alternatively, if an MPT product was 
formulated for topical use (e.g., vaginal gel or ring), 
additional nonclinical safety and pharmacology studies 
might be required, even if the product only included API 
from approved oral dosage forms.  Aside from nonclinical 
safety assessments, a combination product with two (or more) 
approved API might also need to be evaluated from a PK 
perspective in an animal model. 













Activities outlined in blue are necessary for MPT products with only approved API, or with at least one 
experimental API; MPTs with at least one experimental API also require the additional activities outlined in red.    











Figure 2  Optimized timelines for alternative MPT development
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The purpose of this study would be to see if the presence 
of multiple drugs in the formulation had an effect on 
PK or drug distribution relative to what is observed 
individually with these drugs. Vaginal formulations will be 
required to undergo safety and PK testing, typically in a 
rabbit model system.  This would likely involve alternative 
dose combinations (high, medium, low doses of API1 
with high, medium, low doses of API2).  Additional vaginal 
exposure studies may also be needed to appropriately 
bridge the product formulation to data obtained from 
previous studies involving oral dosing (e.g., chronic toxicity, 
reprotoxicity). 
Regarding efficacy, a justification for the product 
components and selected doses will be necessary.  This 
could be achieved via a combination of in vitro, ex vivo, 
and possibly   in vivo animal systems. Minimally, detailed in 
vitro infection studies with the ARV (or anti-STI) will be 
necessary, conducted alone and possibly in combination 
(depending on the product configuration) in the presence 
of semen and cervical-vaginal fluids. In the case of anti-
HIV combination products, evaluation of efficacy in the 
tissue explant model is also recommended.11 Mechanism of 
action (MoA) studies from the individual approved drugs 
should be adequate for the combination product. However, 
studies may also be needed to evaluate the effect of the 
ARV on the activity of the other component, and the effect 
of the other component on the activity of the ARV.
In the case of vaginal ring delivery of combination products, a 
biocompatibility program will be needed for a first-in-humans 
study.  This will involve a series of extraction procedures 
with polar and nonpolar solvents under mild to harsh 
conditions.  Those extracts compatible with in vitro and  in 
vivo safety assessments will be tested in various systems 
to determine if elements of the device, or the device-
drug(s) combination, have a potential safety risk.  The 
harsher condition extractions conducted with organic 
solvents will be necessary to look for device material 
degradation products, heavy metals, or other extractables 
creating potential safety risks for the products. Specific 
biocompatibility assessments need to be defined in 
conjunction with regulatory agencies. Similarly, although 
not necessary for Phase 1 studies with a combination 
product, it will be necessary to conduct formal leachables 
studies in the primary packaging for these products.
Quality 
A major advantage of using approved drugs in an MPT 
combination product is that the API material has satisfied 
all quality requirements (i.e. CMC).  Thus, the good 
manufacturing practice (GMP) as well as necessary 
analytical methods for material analysis (e.g., release and 
stability testing) have been adequately validated. IND 
applications for MPT products using approved drugs 
should be able to cross-reference the approved new 
drug application (NDA) for the 
API (similar to the process used 
to reference the approved API 
nonclinical and clinical data). 
Combination MPT products 
will involve novel formulation 
development.  The entire DP section 
of the IND (Section 7.2) will need 
to be generated. Use of approved 
drugs in the MPT product will not 
reduce the development effort or 
regulatory burden associated with 
the final product formulation.  The 
quality requirements for an MPT 
product will be similar to those 
required for single-agent, single-
indication products. However, 
there will likely be greater 
complexity on the technical 
development of manufacturing 
processes and analytical methods. 
Figure 3  Potential studies to be initiated during development phases 
Source: Eurofins, “Integrated approach of drug development.” http://www.eurofins.com/
pharma-services/pharma-early-development.aspx. Accessed 26 September 2012.
Nonclinical Development Clinical Phases Commercialization
DMPK
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The nature of the requirements will be a function of the 
product’s stage of development.  As the MPT product 
advances from Phase 1 through Phase 3 and on to 
an NDA, the quality requirements will increase and 
become more stringent. For early clinical work (Phase 
1), some of the major requirements include: formulation 
composition, excipient quality, manufacturing process and 
control, packaging, initial product specifications, qualified 
analytical methods for release and stability testing, 
stability data from multiple batches, and a certificate of 
analysis for clinical supplies.  As the process and methods 
become more refined through continued development 
of the DP, any changes and validations will need to be 
documented and described.  Any excipient changes (new 
excipients or new raw materials sources) will need to 
be described and qualified.  Additional stability data will 
need to be reported as well.  As the product progresses 
to Phase 3, the specification limits must be narrowed 
and justified.  Additional assessments will include: physical 
chemical characterization, finalization of container 
closure, definition of critical process parameters for 
design of experiment (DOE)-based quality by design 
(QBD) manufacturing,1,2,3 validation batch production 
and characterization, and so forth. In addition to the drug 
product material requirements, it will be necessary to 
develop and validate equipment cleaning procedures for 
the manufacturing equipment that produces the drug 
product.
MPT Case Study Number 2:  
Combination products that include one 
or more experimental drugs and/or 
devices
Using experimental components in a new MPT product 
will require significantly more nonclinical and quality-
related efforts.  Typically, an experimental API, or new drug 
entity (NDE), is progressed through nonclinical evaluations 
in parallel with quality-related development.  Toxicological 
or other issues may be identified, requiring additional 
follow-up studies that add cost and time to the 
development program. In some cases, this could result in 
“no go” development decisions for a product. Developing 
MPTs with one or more NDEs has inherently more risk 
and expense.  This additional risk dictates the need for 
comprehensive nonclinical assessments and detailed quality 
evaluations so that major impediments to development 
can be identified early on, potentially saving significant 
effort and investment in products that are not appropriate 
as MPT candidates. 
Nonclinical evaluation of MPT products with 
experimental components will require a range of 
nonclinical studies depending on the indication, 
route of administration, and physical-chemical 
properties of the drug and/or device. In the case 
of anti-HIV compounds, nonclinical virology studies 
will be needed.  These typically include in vitro effective 
concentration (EC50) determinations for lab-adapted 
strains as well as with primary viral isolates across viral 
clades in peripheral blood mononuclear cells (PBMC). 
Other specialized assays (e.g., dendritic cell model) as well 
as ex vivo (human explant tissue) and in vivo (e.g., nonhuman 
primate) models may be part of the virology package. 
MoA characterization will be required as will studies 
looking at the development of resistance.  A complete 
safety pharmacology package will also be required.  The scope 
of this package will depend on whether or not the drug is 
administered systemically or topically (and if administered 
topically, how much absorption is achieved). Secondary 
pharmacology studies looking at other targets (e.g., 
enzymes, ion channels, receptors) are typically required 
as well. Genotoxicity will need to be assessed with at 
least two methods; specific systems to be evaluated might 
include central nervous system, cardiovascular, and/or 
respiratory.  These assessments can be made by individual 
studies, or as part of a panel of more general studies 
including single and repeat dose toxicology studies, dose 
ranging studies, and long-term chronic toxicity studies (e.g., 
six months in dogs, nine months in rabbits).  The need for 
and nature of these studies will be determined by data 
obtained through the course and stage of development, 
and the intended route of administration.
Importance of PK Studies 
PK studies in animals are necessary for several 
reasons.  They confirm the level of drug exposure, assuring 
that safety is established in the presence of the drug.  They 
also help validate the species used in the preclinical 
investigations by confirming that the pharmacokinetic 
profiles are similar to that observed with humans. In 
addition, these studies enable safety margins to be 
established based on the higher exposures achieved in 
animals versus those seen in humans. In the case of MPTs, 
PK studies can also help define whether any interactions 
between APIs alter the way they are absorbed, distributed, 
6    Nonclinical Development Needs and Regulatory Requirements for MPTs: A Primer
metabolized, or excreted from the body that may need 
to be addressed in product design.  The extent of PK work 
necessary will depend on the route of administration of the 
product and the extent to which the APIs are absorbed. 
A PK package will be necessary, including single and repeat 
dose studies conducted in multiple species with plasma and 
tissue drug level determinations.  These studies will involve 
standard calculations of such parameters as maximum 
concentration (Cmax), time to maximum concentration 
(Tmax), area under curve (AUC), and time to 50 percent 
reduction (T1/2). Repeat dose PK can be evaluated during 
toxicology studies. Distribution studies at some level 
will likely be required (e.g., whole body autoradiography 
with radiolabeled drug); however, specific metabolism and 
elimination study requirements will depend on the drug, 
route of administration, absorption, and PK profiles.
Specialized toxicology studies will be needed for MPT 
products, including reprotoxicity (segments 1, 2, and 3), 
guinea pig sensitization, and other assessments depending 
on the drug and product configuration.  This may include 
the biocompatibility types of studies described earlier 
for device-based delivery. Finally, NDE will require 
carcinogenicity studies in one or two species. 
It is not possible to predesign a complete nonclinical package 
for NDE that would be necessary for NDA approval.  The 
above summary of potential studies outlines what might 
be part of a typical NDE nonclinical package.  Additional 
guidance is available12 for the nonclinical evaluation of 
microbicide-type products that may be useful for certain 
MPT products. However, the specific studies needed to 
support a product are to a significant degree determined 
through the course of the overall development of the 
product. Ultimately, the necessary nonclinical studies for 
a given product are determined through interactions with 
regulatory authorities.
NDE quality
The same drug product requirements discussed earlier 
for an MPT drug product involving approved drugs would 
apply to a formulated product achieved with NDE(s) 
as the API(s).  The major difference in quality requirements 
for an MPT using an approved drug and an MPT using an 
NDE is at the level of the drug substance.  Approved drugs 
presumably have the benefit of a full drug substance 
quality package; experimental drugs need to generate such 
a package through the course of product development. 
Depending on the nature of the NDE, the drug substance 
quality packages could vary significantly. For example, the 
requirements for a small organic molecule will be quite 
different than those of a recombinant protein API.  The 
requirements of either of these types of entity would 
differ even further from a probiotic product.  Thus, it is 
difficult to provide a comprehensive overview of drug 
substance quality requirements for all possible MPT 
options. Minimally, a quality package for a small organic 
molecule API would likely require physical-chemical 
characterization, solubility profiles, stability assessments 
under different conditions (e.g., temperature, moisture, 
light, oxidation, etc.), route of synthesis definition, analytical 
methods development and validation, process scale up, and 
specifications with justifications. Other more specialized 
characterizations could include polymorph definition, 
sterility (if needed), and microbe testing.  As in the case of 
drug product manufacture, experimental API production 
will involve definition of critical process parameters, and 
DOE-type process development for QBD production at 
commercial scale. Multiple batches of the experimental 
API with full stability assessments will be required, as will 
validation batch production and characterization. Packaging 
and container closure will need to be addressed for API, 
similar to what was described for the drug product. 
MPT products can be configured with device 
technologies either as a means of achieving active 
drug delivery or as a means of directly achieving 
efficacy for one or more intended indications. Vaginal 
ring products described earlier serve as the most 
common example of MPT products where the device 
serves exclusively as the means of delivering the active 
pharmaceutical agents necessary for the dual indication 
efficacies.  Typically, regulatory review of such products 
is achieved from the perspective of the active drugs, not 
the delivery mechanism. For example, primary review at 
the U. S. Food and Drug Administration (FDA) of a vaginal 
ring delivering an antiviral and hormonal contraceptive 
would likely occur with the Center for Drug Evaluation 
and Research (CDER). However, additional review of such 
a product would be provided by the Center for Devices 
and Radiological Health (CDRH).  Alternatively, a device 
responsible directly for an efficacy outcome could be 
reviewed primarily by CDRH.  Agency guidance for barrier 
devices for contraception and STI prevention are available 
via the CDRH.13 
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Summary
The FDA, European Medicines Agency (EMA), and ICH 
have produced guidance documents that provide summary 
information on the nonclinical and quality requirements 
for pharmaceutical product development.  Although no 
specific guidance documents exist for the development of 
MPT products for SRH indications, a number of relevant 
guidance documents do exist and have been summarized 
elsewhere.14 Every pharmaceutical product will 
have its own specific requirements for development 
and regulatory approval, and communication with 
regulatory agencies is a key element of a product 
development effort. Understanding the requirements 
at different stages of product development is critical 
for efficient, cost effective, and successful product 
development. For MPT products with elevated 
development complexities and risks, a thorough 
understanding of the regulatory requirements is all the 
more essential. 
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